ArticleClinical ophthalmology (Auckland, N.Z.)2025
Treatment Adherence in Myopia Progression Management: A Monocentric Retrospective Study on Rates and Determinants.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify factors influencing good adherence when using different myopia management solutions, including low-dose atropine, defocus spectacle lenses (DIMS), defocus contact lenses, photobiomodulation with low-intensity red light, and combined approaches. Design: Retrospective, observational, single-center chart review. Patients and Methods: This single center retrospective study analyzed clinical and demographic data of myopic patients younger than 17 years. Exclusion criteria were presence of systemic and ocular pathologies, significant refractive (other than myopia) or binocular vision disorders, and follow-up less than 6 months. Data on age, sex, cycloplegic refraction, myopic progression, type of myopia control treatment, and patient-reported adherence to treatment (categorized as good, fair, poor) was obtained from the medical charts. Results: We analyzed 177 Caucasian pediatric patients (49.2% female; mean age 11.1 ± 2.78 years); 84.2% reported good adherence to treatment, 6.8% reported moderate adherence, and 9.0% reported poor adherence. In multivariate logistic regression analysis, DIMS spectacle lenses showed the strongest association with adherence (OR = 21.17, p = 0.003), followed by the combined use of DIMS spectacle lenses and atropine (OR = 4.02, p = 0.038). Higher myopia progression in spherical equivalent (SE) (OR = 0.31, p = 0.002), and older age (OR 0.78, p = 0.05) were significantly associated with lower adherence. Conclusion: These findings suggest that younger age and lower myopia progression are associated with better adherence to treatment. Among treatment options, DIMS spectacle lenses alone or combined with atropine, were the strongest predictors of adherence, while other approaches showed no significant associations. This favors optical-based strategies when adherence is a concern and calls for enhanced counseling strategies in adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.